Key result
Rutin co-treatment reverses chemotherapy-induced cardiotoxicity and preserves cardiac function across preclinical models.
Why the study?
Chemotherapy can cause significant heart toxicity, and the phyto-antioxidant rutin has potential to regulate oxidative stress, inflammation, and apoptosis, prompting a systematic evaluation of its efficacy in protecting the heart against injury induced by chemotherapeutic agents.
Does co-treatment with rutin prevent chemotherapy-induced cardiac injury and maintain heart function in non-clinical chemotoxicity models?
Systematic Review
Does co-treatment with rutin prevent chemotherapy-induced cardiac injury and maintain heart function in non-clinical chemotoxicity models?
This systematic review of 14 preclinical studies demonstrates that rutin mitigates chemotherapy-induced cardiotoxicity via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms, warranting future clinical trials.
Answers are grounded in this paper and cite their sources.
Rutin may mitigate chemotherapy cardiotoxicity; extends antioxidant evidence and supports randomized trials before practice change.
Chemotherapy remains a crucial part of cancer treatment, markedly alleviating the societal burden of the disease. Nonetheless, the advantageous therapeutic effects of these drugs are generally accompanied by significant unfavorable consequences, including damage to healthy tissues, with heart toxicity being a primary concern. Rutin, a phyto-antioxidant, has considerable potential to regulate disorders associated with oxidative stress, inflammation, and apoptosis. This review systematically evaluates the efficacy of rutin in protecting the heart against injury induced by chemotherapeutic agents. In this study, the search terms were selected based on the research purpose and used to examine the titles and abstracts of papers. After a comprehensive examination of the literature in databases (PubMed, ISI, and Scopus) up to December 2025, adhering to PRISMA guidelines, 193 papers were evaluated, and 14 studies were chosen based on established inclusion and exclusion criteria. Data analysis revealed that many categories of chemotherapeutic drugs induce detrimental cardiac side effects in both in vitro and in vivo models. Co-treatment with rutin significantly reversed detrimental changes and maintained heart function and physiological parameters. The preventive properties of rutin primarily stem from its ability to reduce oxidative stress, downregulate inflammatory pathways, and prevent cell death. Although preliminary findings from animal studies suggest potential benefits of co-administering rutin with chemotherapy, additional clinical trials are necessary to determine whether rutin may compromise the efficacy of chemotherapeutic agents and to evaluate its safety and effectiveness as a cardioprotective supplement for cancer patients.
No takes yet. Share an insight, caveat, or question.
Heidary et al. (2026) conducted a systematic review in Chemotherapy-induced cardiotoxicity. Rutin vs. Chemotherapy without rutin was evaluated on Cardioprotective efficacy (heart function, physiological parameters, oxidative stress, inflammatory pathways, and cell death). Rutin co-treatment across 14 preclinical studies reversed chemotherapy-induced cardiotoxicity and maintained cardiac function via antioxidant and anti-inflammatory effects.
Synapse has enriched 10 related papers. Consider them for comparative context: